TongjiHospital Trials - LARVOL Sigma

TongjiHospital	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

luo, xiaoping

NCT05341115 / 2022-002471-11: A Study of Leuprolide Acetate Depot in Children With Central Precocious Puberty

Recruiting

RoW

Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M

Takeda, Takeda

Central Precocious Puberty

05/25

NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia

Recruiting

RoW

Recombinant human growth hormone

GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University

Achondroplasia

02/25

NCT05144035: A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants

Recruiting

138

RoW

PEG-rhGH, jintrolong

Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd.

Small for Gestational Age Infant, Growth Hormone Treatment, Cognitive Developmental Disorder

12/25

06/26

NCT05529992 / 2022-002323-35: A Study of Velaglucerase Alfa (VPRIV) in Chinese Children, Teenagers, and Adults With Type 1 Gaucher Disease

Completed

RoW

Velaglucerase Alfa, VPRIV

Takeda, Takeda

Gaucher Disease

08/24

NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty

Recruiting

US, RoW

Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide

Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd.

Puberty; Precocious, Central

11/25

06/26

NCT04513171: Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children

Completed

2/3

434

RoW

Y-shape pegylated somatropin, Norditropin®, Norditropin

Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital

Growth Hormone Deficiency

06/23

07/23

NCT03255694: A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature

Active, not recruiting

360

RoW

PEG-somatropin, Polyethylene Glycol Recombinant Human Somatropin Injection

GeneScience Pharmaceuticals Co., Ltd., Tongji Hospital, The First Hospital of Jilin University, Affiliated Hospital of Jiangnan University, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Fudan University

Dwarfism

06/30

Gensci032-401, NCT06722079: A Real-world Study of Long-acting Growth Hormone Injection for Turner Syndrome

Completed

N/A

743

RoW

Changchun GeneScience Pharmaceutical Co., Ltd., Tongji Hospital

Turner Syndrome

06/23

Sobi.NTBC-008, NCT06227429: A Non-interventional, Post-Marketing Study to Describe Outcome of Nitisinone Treatment in HT-1 Patients

Recruiting

N/A

RoW

Nitisinone, Orfadin®

Swedish Orphan Biovitrum

Hereditary Tyrosinemia, Type I

06/27

NCT05137301: Performance of the Diagnostic Value of Bone Age Assessment Software Based on Deep Learning in Chinese Children

Recruiting

N/A

1000

RoW

X-ray bone age instrument

Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd.

Endocrine Diseases

12/24

ZHAO, Jianping

CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

HAIC, hepatic arterial infusion chemotherapy of FOLFOX, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Lenvatinib, Lenvima, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga, apatinib plus camrelizumab, Apa plus C, Anti-PD-1 monoclonal antibody, PD-1 inhibitor

Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., The Second Affiliated Hospital of Fujian Medical University

Hepatocellular Carcinoma Non-resectable

04/24

12/24

NCT04462185: A Prospective Cohort Study of Chinese Patients With Pulmonary Nodules: Prediction of Lung Cancer Using Noninvasive Biomarkers

Recruiting

N/A

3000

RoW

A genomic and transcriptomic landscape analysis

AnchorDx Medical Co., Ltd., The First Affiliated Hospital of Guangzhou Medical University, Tongji Hospital, Qilu Hospital of Shandong University, Shanghai Zhongshan Hospital, West China Hospital, Beijing Chao Yang Hospital, Johnson & Johnson (China) Investment Ltd.

Pulmonary Nodules

06/24

12/24

NCT03651986: Diagnostic and Monitoring Significance of ctDNA Methylation Analysis by NGS in Benign and Malignant Pulmonary Nodules

Active, not recruiting

N/A

10560

RoW

ctDNA methylation analysis by NGS

AnchorDx Medical Co., Ltd., Xiangya Hospital of Central South University, West China Hospital, Shanghai Zhongshan Hospital, Shanghai Pulmonary Hospital affiliated to Tongji University, First Hospital of China Medical University, Guizhou Provincial People's Hospital, Shanghai Chest Hospital, First Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital Xi'an Jiaotong University, Qilu Hospital of Shandong University, Inner Mongolia People's Hospital, The First Affiliated Hospital with Nanjing Medical University, The First Affiliated Hospital of Zhengzhou University, Second Hospital of Jilin University, LanZhou University, Peking University Third Hospital, The First People's Hospital of Yunnan, Shantou Affiliated Hospital of Sun Yat-Sen University, Ruijin Hospital, The Shanghai Jiao Tong University Medical School, Tongji Hospital, The First Affiliated Hospital of Guangzhou Medical University, Xijing Hospital, Air Force Medical University of PLA, Shenzhen People's Hospital, Henan Provincial People's Hospital, Beijing Chao Yang Hospital, Xiamen Second Hospital, The First Affiliated Hospital of Nanchang University

Pulmonary Nodules

09/24

06/25

Luo, Xin

NCT06717152: Efficacy and Safety of SJP-0132 Eye Drops in Chinese Patients With Dry Eye Disease

Recruiting

400

RoW

SJP-0132, Placebo

Senju Pharmaceutical Science & Technology (Beijing) Co., Ltd., Senju Pharmaceutical Co., Ltd.

Dry Eye

07/25

08/25

NCT04694781: Study of LVGN6051 (CD137 Agonist Antibody) in Advanced or Metastatic Malignancy

Completed

RoW

LVGN6051, Pembrolizumab

Lyvgen Biopharma Holdings Limited

Cancer

10/23

CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

Hepatocellular Carcinoma Non-resectable

04/24

12/24

Ding, Ze-yang

CCGLC-012, NCT06192784: Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangiocarcinoma

Recruiting

RoW

DEB-TACE, drug eluting beads-transcatheter arterial chemoembolization, Lenvatinib plus pucotenlimab, levima plus pucotenlimab

Tongji Hospital, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)

Cholangiocarcinoma Non-resectable

01/25

06/25

CCGLC-007, NCT05533892: Nocardia Rubra Cell Wall Skeleton (N-CWS) Plus HAIC, Lenvatinib and Tislelizumab in Treating Patients With Advanced HCC

Recruiting

RoW

Nocardia rubra cell wall skeleton, N-CWS, Hepatic arterial infusion chemotherapy, HAIC, Lenvatinib, JieLiEn, Tislelizumab, BaiZeAn

Wan-Guang Zhang, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, M&R Pharm, Geneplus-Beijing Co. Ltd., Yuce Biotechnology Co., Ltd., Geneis, Simcere Pharmaceutical Co., Ltd, BeiGene, Haplox Biotechnology Co., Ltd.

Hepatocellular Carcinoma

08/24

02/25

CCGLC-009, NCT06194695: DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma

Recruiting

N/A

100

RoW

drug eluting beads-transcatheter arterial chemoembolization, DEB-TACE, envatinib plus anti-PD(L)1

Ze-yang Ding, MD, Geneplus-Beijing Co. Ltd., Chinese Cooperative Group of Liver Cancer (CCGLC)

Cholangiocarcinoma Non-resectable

12/24

06/25

TACE-TKI-ICI, NCT05717738: Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

TACE, transarterial chemoembolization, Lenvatinib, levima, Anti-PD-1 monoclonal antibody, PD-1 inhibitor, Bevacizumab Biosimilar IBI305 plus sintilimab, Byvasda (B) plus S, Bevacizumab plus Atezolizumab, Avastin plus Tecentriq, apatinib plus camrelizumab, Apa plus C, Sorafenib, Nexavar, Donafenib, Zepsun, Regorafenib, stivarga

Tongji Hospital, Chinese Cooperative Group of Liver Cancer, Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, The Second Affiliated Hospital of Fujian Medical University, Geneplus-Beijing Co. Ltd., Haplox Biotechnology Co., Ltd.

Hepatocellular Carcinoma Non-resectable

12/23

12/24

CCGLC-001, NCT05713994: Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

Recruiting

N/A

300

RoW

Hepatocellular Carcinoma Non-resectable

04/24

12/24

CCGLC-002, NCT05520801: Primary Hepatobiliary Cancer Cohort of Central China

Recruiting

N/A

2000

RoW

Tongji Hospital, Chinese Cooperative Group of Liver Cancer (CCGLC), Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province, Haplox Biotechnology Co., Ltd., Geneplus-Beijing Co. Ltd., YuceBio Technology, Gelesis, Inc.

Hepatocellular Carcinoma, Biliary Tract Neoplasms

12/24

03/25

XIAOHUA, ZHU

No trials found

zhu, xiaohua

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites